



Contact:

David Waldman or Justyna Gudaszevska

Crescendo Communications, LLC

Email: mmd@crescendo-ir.com

Tel: +48 693 354 580

Milestone Medical Unveils CompuFlo® Epidural Trainer and Educational Suite at Euroanaesthesia 2019

Connecting technique and intelligence accelerates clinical competency

LIVINGSTON, NJ, May 30, 2019 – Milestone Medical Inc. (WAR: MMD) today announced that its new CompuFlo® Epidural Trainer (CompuFlo Trainer), an instructional instrument that uses pressure sensing technology to improve confidence and success in epidural placements, is making its debut to thousands of anesthesia professionals at this week's Euroanesthesia 2019 Congress. Milestone Medical is entering the medical education market with a full suite of learning tools to improve epidural placement by trainees:

- **CompuFlo Trainer & Disposables** – A digital console built on patented Dynamic Pressure Sensing® platform with touch-screen monitor and internal pressure transducer developed by Milestone Scientific Inc., the licensor and the majority shareholder of Milestone Medical Inc. A multi-use, non-sterile disposable kit designed for 100 training procedures.
- **Skill Lab** - 24/7 online access to instrument instruction, clinical literature and resources. Trainees can self-study in advance of CompuFlo Trainer use or refresh at any time.
- **Procedure Log** - Subscription to a mobile-responsive tool that captures the results of epidural procedures. Ideal for lab groups to review performance and monitor skill development.

A Leap Forward in Anesthesia Training

Traditional loss-of-resistance technique relies on subjective factors to identify entry to the epidural space, which make insertion a difficult procedure to master for trainees. Studies show up to 90 patient epidural placements may be necessary to reach basic clinical competency.¹

The CompuFlo Trainer links trainee tactile feel with visual and audible confirmation of pressure changes to verify the epidural space. CompuFlo's real-time Dynamic Pressure Sensing technology® detects tissue changes that are imperceptible by touch. This intelligence allows the trainee to objectively discriminate between true and false loss of resistance and confirm location.

Instruction becomes more efficient as instructors, who previously depended solely on trainee feedback of their tactile feel, have visual and audible feedback of trainee needle movement during a procedure. Documentation is also generated for each procedure for review and trainee performance monitoring.

"Medical residency programs and simulation labs now have a complete training solution available to accelerate the procedure's learning curve by reducing stress, uncertainty and the number of attempts to locate the epidural space," comments Leonard Osser, Interim Chief Executive Officer of Milestone Medical. "This digital educational suite enhances teaching and learning by building confidence through intelligence not previously available to instructors and trainees."

CompuFlo Trainer explainer video highlights trainee needs: <https://youtu.be/7EJCa1OAjgk>

The CompuFlo Epidural Trainer is not intended for human use. Milestone Medical previously announced an agreement with American 3B Scientific, a leading supplier of didactic material for medical education, to distribute the CompuFlo Trainer in North America, Central America and select countries in South America.

1 D. J. Kopacz, J. M. Neal, and J. E. Pollock, "The regional anesthesia 'learning curve.' What is the minimum number of epidural and spinal blocks to reach consistency?" *Regional Anesthesia*, vol. 21, no. 3, pp. 182–190, 1996.

About Euroanaesthesia 2019

Held June 1 – 3 in Vienna, Austria, Euroanaesthesia is Europe's largest annual event showcasing the latest news and innovations with medical experts active in the field of anesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment. This international event gathers upwards of six thousand delegates from around the world.

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical device company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary *DPS* Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

#